There's a particular kind of anxiety that comes with managing a chronic autoimmune condition during pregnancy. You're already navigating the tension between keeping your disease stable and protecting a developing baby. Then comes a vaccine appointment — and suddenly you're in a forum at 11pm trying to read twelve different threads about whether your Humira is going to interfere with the Tdap, whether getting the RSV shot will trigger a flare, whether your baby is going to have enough protection if your immune system isn't "working normally."

That anxiety is legitimate. It's also, in many cases, based on fear that mixes together two very different categories of vaccine — and a general dread of immune-related interventions that can feel overwhelming when you're already on immunosuppressive therapy.

This article tries to untangle that. Not to tell you what to decide — that's a conversation for you, your rheumatologist, your gastroenterologist, and your OB — but to give you the clearest possible picture of what the current evidence says, what doctors typically think through, and what women in your situation are actually experiencing.

Why Biologics Create Vaccine Anxiety in the First Place

Context Biologics like TNF inhibitors, IL-12/23 inhibitors, and integrin antagonists work by targeting specific immune pathways. This targeted suppression is what makes them effective for RA, Crohn's, ulcerative colitis, and psoriasis — and it's also what makes many patients and even some healthcare providers cautious about vaccines.

The concern is reasonable in principle. If your immune system is being modulated, will it respond adequately to a vaccine? And if you're pregnant, will that response — or lack of it — affect how much protection gets transferred to your baby through the placenta and breast milk?

These are real questions. But they apply differently depending on the type of vaccine. And the type distinction is crucial here.

Live Vaccines vs. Inactivated Vaccines: The Distinction That Changes Everything

Vaccines fall into two broad categories that carry fundamentally different risk profiles for immunosuppressed patients:

  • Live attenuated vaccines — such as MMR (measles, mumps, rubella), varicella (chickenpox), and intranasal FluMist — contain weakened but living organisms. In people with significantly suppressed immune systems, these can theoretically cause actual infection. These are generally contraindicated during pregnancy regardless of biologic use.
  • Inactivated vaccines — such as Tdap, the injected flu shot, COVID-19 vaccines, and the maternal RSV vaccine — contain killed pathogens or protein components. They cannot replicate. They cannot cause infection. The theoretical concern about live vaccine replication simply does not exist for these.

Both the Tdap vaccine and the RSV maternal vaccine (Abrysvo, by Pfizer) are inactivated. This is not a minor footnote — it changes the entire risk calculation.

Key Clinical Insight

According to current ACR (American College of Rheumatology) guidance, inactivated vaccines can generally be administered to patients on biologic therapy without stopping or delaying the medication. The recommendation is to vaccinate — not to avoid vaccination out of generalized immune concern. The specific question of optimal timing around biologic dosing is a separate, nuanced conversation that involves your individual treatment schedule.

What These Vaccines Actually Do During Pregnancy — And Why They're Recommended

Both vaccines work through a mechanism called maternal immunization — the idea that by vaccinating the mother, you generate antibodies in her blood that then cross the placenta and provide the newborn with temporary passive immunity during the first weeks of life, before the baby can be vaccinated themselves.

This is particularly important because:

  • Whooping cough (pertussis) is most dangerous — and most lethal — in babies under three months old. Infants cannot receive their first DTaP vaccine until two months of age, leaving a gap of weeks where maternal antibodies are their only protection. In the United States, most pertussis deaths occur in infants under two months old.
  • RSV (respiratory syncytial virus) is the single leading cause of infant hospitalization in the United States, responsible for roughly 58,000–80,000 hospitalizations in children under five annually. The maternal RSV vaccine, recommended between 32–36 weeks of gestation, is designed to ensure the baby is born with RSV-specific antibodies in that critical first window of life.

This context matters when you're weighing risks. The question isn't just "could the vaccine affect my disease?" — it's also "what is my newborn's risk if I don't vaccinate?"

Tdap vs. RSV Vaccine: Key Facts for Women on Biologics

Feature Tdap (Whooping Cough) RSV Maternal Vaccine (Abrysvo)
Vaccine type Inactivated — acellular components Inactivated — protein subunit
Contains live organisms No No
Recommended timing in pregnancy 27–36 weeks (each pregnancy) 32–36 weeks
Currently recommended with biologics Yes — per CDC, ACOG, ACR Yes — no contraindication for biologics
May biologics reduce antibody response? Possible modest reduction with some TNF-i Under active investigation
Flare risk reported Low — mostly anecdotal mild effects Low — limited but reassuring early data
Alternative for baby if mother unvaccinated Cocooning (vaccinate all household contacts) Nirsevimab (Beyfortus) monoclonal antibody at birth

What Women on Biologics Are Actually Reporting

Online communities — particularly forums on Inspire.com, Reddit's r/CrohnsDisease and r/rheumatoid, and Facebook groups for RA and IBD pregnancy — have become a significant source of peer experience sharing for this exact question. These are not clinical trials. They are not controlled data. But they represent something that clinical literature often lacks: lived experience from real people navigating the same situation you are.

Across hundreds of posts and threads spanning multiple years, some consistent patterns emerge — alongside important variability:

Sore arm at injection site
The most universally reported experience — typically 1–3 days, often more pronounced with the RSV vaccine than Tdap. Some women describe it as more intense than non-pregnancy vaccinations.
Very common
Temporary fatigue
A day or two of increased tiredness reported frequently. Many note it's difficult to distinguish from pregnancy fatigue baseline. Most describe it as manageable and short-lived.
Common
Mild low-grade fever
Some women on TNF inhibitors report a mild temperature elevation for 24 hours. Typically self-resolving. Worth monitoring and reporting to your care team if it persists.
Occasional
Transient joint sensitivity
A small number of women with RA report a brief increase in joint awareness or mild tenderness lasting 1–5 days post-vaccination. Most describe it as not meeting the threshold of a true flare.
Occasional
No notable effects at all
A significant proportion of women report nothing beyond a standard sore arm — no change in disease activity, no extra fatigue beyond their norm, no disruption to their pregnancy or biologic schedule.
Very common
Significant disease flare
Reports of clear, significant post-vaccination flares are uncommon in the communities surveyed. They exist, but they represent a small minority of accounts — and causal attribution is difficult in a complex biological context.
Uncommon
A Note on Anecdotes

Online experiences are genuinely valuable — they tell you what the range of outcomes looks like in real people. But they have real limits. People who have difficult experiences are more likely to post than people who have uneventful ones. Disease activity during pregnancy fluctuates for many reasons beyond vaccines. And individual biology, specific biologic used, disease type, and disease stability all vary enormously. Treat community reports as useful context, not as predictions of your own experience.

What Your Specialists Actually Think Through

When a rheumatologist or MFM specialist is advising a pregnant patient on biologics about vaccination, the conversation is rarely as simple as "yes" or "no." Several factors inform their thinking:

Disease Stability

If your autoimmune disease is in a significant flare at the time of the proposed vaccination, some specialists may prefer to stabilize first. Active inflammation changes the immune environment, and there's logic to not introducing additional immune stimulation during a flare — though the evidence base for this specific timing decision in pregnancy is limited. Most specialists would still prioritize vaccinating within the recommended pregnancy window over delaying indefinitely.

Biologic Type and Mechanism

Not all biologics work the same way. TNF inhibitors (adalimumab/Humira, etanercept/Enbrel, infliximab/Remicade, certolizumab pegol/Cimzia) suppress tumor necrosis factor and have a broader immune-modulatory effect. Some studies in non-pregnant adults suggest modest antibody titer reductions with some vaccines. Integrin antagonists like vedolizumab (Entyvio) work primarily in the gut and may have less systemic immune impact. IL-12/23 inhibitors like ustekinumab (Stelara) and IL-23 inhibitors like risankizumab (Skyrizi) target different pathways again.

Your specific biologic matters — and your rheumatologist will know the nuances of your particular situation in a way that general guidance cannot capture.

Biologic Dosing Timing

Some specialists discuss whether to time vaccination relative to the biologic dosing cycle — for example, vaccinating mid-cycle when drug levels may be at a trough, theoretically allowing a slightly fuller immune response. The evidence for this strategy in pregnancy specifically is limited, and it needs to be weighed against the risk of widening a biologic gap in a high-inflammatory period. This is not standard universal guidance — it's a discussion to have with your specific rheumatologist.

Trimester Considerations

Placental transfer of maternal antibodies to the fetus increases significantly in the third trimester. Vaccination in the 27–36 week window is timed specifically to maximize this transfer — generating peak maternal antibody levels precisely when transfer is most active. This timing holds for women on biologics too, unless there's a specific clinical reason to adjust.

The Baby's Biologic Exposure

Many biologics — particularly large-molecule TNF inhibitors like infliximab, adalimumab, and ustekinumab — cross the placenta actively, particularly from the second trimester onward. This means your newborn may be born with measurable levels of your biologic in their blood. Your pediatrician needs to know this, because it typically means avoiding live vaccines (like rotavirus) in the baby's first 6 months. This is separate from the question of your own pregnancy vaccination, but it's part of the same conversation that your care team should be having with you before delivery.

Making the Most of the Conversation With Your Specialist Team

Many women report that this conversation doesn't always happen proactively — rheumatology nurses and IBD nurse specialists are often the most accessible point of contact for these questions, and they're frequently better equipped than a general OB for the biologic-specific nuances.

If your OB seems unfamiliar with the biologic-specific considerations, that's worth noting — this is an area where rheumatology and gastroenterology input is genuinely valuable, and a quick communication between your specialists can clarify what's best for your individual situation.

The Research Picture: What We Know and What's Still Being Studied

The MAMA Study: Why It Matters to You

The MAMA study (Maternal Anti-infective Medications and Antibody transfer, along with related research initiatives) is among the ongoing efforts specifically examining how maternal biologic therapy affects vaccine-induced antibody transfer to newborns. This research is asking exactly the questions that don't yet have definitive answers: does taking a TNF inhibitor meaningfully reduce how much Tdap or RSV antibody your baby receives? Does the specific biologic matter? Does trimester timing of the vaccine interact with biologic use? Results from these studies, expected to generate published data in the coming years, will significantly sharpen guidance for immunosuppressed pregnant women in ways that current recommendations simply cannot yet address.

What the current literature does suggest — mostly from non-pregnant populations and extrapolated data — is that some TNF inhibitors may modestly reduce antibody titers to certain vaccines. The clinical significance of this "modest reduction" in terms of actual infant protection is not yet well-established. It may be meaningful; it may be within the protective threshold; it likely varies by biologic, individual immune response, and vaccine type.

The honest answer to "will my biologic reduce my baby's vaccine-derived protection?" is: possibly, somewhat, in some cases — and ongoing research is actively trying to give us a better answer than that. This uncertainty is real, and it's part of why the risk-benefit conversation matters. Going unvaccinated has its own impact on your baby's protection — one that is more certain than the potential modest attenuation from biologic therapy.

When to Contact Your Doctor After Vaccination

Most post-vaccination experiences for women on biologics fall within the expected range: a sore arm, some fatigue, perhaps a day of low-grade fever. But some symptoms warrant prompt contact with your care team:

It's also worth keeping a simple symptom log for 5–7 days after vaccination — not because problems are common, but because it gives your care team useful information if anything does change, and it helps you communicate clearly about what you noticed and when.

A Balanced Place to Land

It's understandable to feel conflicted about this. When your immune system is already being managed carefully, introducing anything that interacts with it feels like a risk worth questioning. That instinct isn't irrational — it comes from months or years of learning to pay close attention to your body's signals.

But the evidence currently available points in a consistent direction: Tdap and RSV vaccines are not live vaccines, they are recommended during pregnancy, and biologic use is not a contraindication to receiving them. Most women on biologics who get these vaccines experience typical, manageable reactions without significant impact on disease activity. The primary unknowns — around whether biologic therapy modestly reduces antibody transfer to the baby — are being actively studied, and the current answer is "possibly somewhat" rather than "significantly."

What these vaccines protect against is not abstract. Whooping cough in a one-month-old is a genuine emergency. RSV-related bronchiolitis drives tens of thousands of infant hospitalizations every year. The protection that maternal vaccination provides during those first weeks of life, before your baby can be vaccinated themselves, is real and meaningful.

None of this means the decision is simple, or that your specific circumstances don't matter. They do. Which is why the most useful step — beyond reading articles like this one — is having a direct, specific conversation with your rheumatologist and OB together about your individual medication, your current disease status, and your specific pregnancy timeline. That conversation is the one that will actually guide your decision.

And if your care team doesn't bring this topic up proactively, the questions in the section above are a good place to start.